Notice type: 3rd Party Publications
Problem Or Issue:
Important Safety Information from Pfizer Healthcare Ireland regarding Xeljanz (tofacitinib): initial clinical trial results of increased risk of major adverse cardiovascular events and malignancies (excluding nmsc) with use of tofacitinib relative to tnf-alpha inhibitors
Important Safety Information - Xeljanz (tofacitinib)